Haematopoietic and cardiac GPR55 synchronize post-myocardial infarction remodelling
Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität (LMU) Munich, Pettenkoferstr. 9, 80336 Munich, Germany
German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany
Medical Clinic I, University Clinic Würzburg, Würzburg, Germany
Abstract
While classical cannabinoid receptors are known to crucially impact on myocardial infarction (MI) repair, a function of the cannabinoid-sensitive receptor GPR55 herein is poorly understood. We investigated the role of GPR55 in cardiac physiology and post-MI inflammation and remodelling. Global GPR55−/− and wildtype (WT) mice were basally characterized or assigned to 1, 3 or 28 days permanent MI and subsequently analysed via pro-inflammatory and pro-hypertrophic parameters. GPR55−/− deficiency was basally associated with bradycardia, increased diastolic LV volume and sarcomere length and a subtle inflammatory phenotype. While infarct size and myeloid cell infiltration were unaffected by GPR55 depletion, acute cardiac chemokine production was prolonged post-MI. Concurrently, GPR55−/− hearts exhibited a premature expansion of pro-reparative and phagocytic macrophages paralleled by early up-regulation of extracellular matrix (ECM) factors 3 days post-MI, which could be mimicked by sole haematopoietic GPR55 depletion. Moreover, global GPR55 deficiency mitigated MI-induced foetal gene re-programming and cardiomyocyte hypertrophy, culminating in aggravated LV dilatation and infarct expansion. GPR55 regulates cardiac homeostasis and ischaemia responses by maintaining adequate LV filling and modulating three crucial processes post-MI: wound healing kinetics, cardiomyocyte hypertrophy and maladaptive remodelling.
Untitled section
Subject terms: Immunology, Cardiology, Molecular medicine, Pathogenesis
Article notes
Untitled section
Received 2021 Apr 15; Accepted 2021 Jun 28; Collection date 2021.
Introduction
Coronary artery disease and MI remain the leading causes of death worldwide. The extent of contractile myocardium loss and maladaptive LV remodelling, including infarct thinning and expansion combined with LV volume-overload and dilation, determine the remaining LV function and thereby the patient’s long-term prognosis post-MI. Early after onset of MI, ischaemic cardiomyocytes become necrotic in the infarct area, but also apoptotic in the infarct and border zones while surviving cardiomyocytes in the remote area initiate pro-hypertrophic alterations to provide hemodynamic compensation for the loss of contractile tissue1,2. Simultaneously, tissue-resident immune and non-immune cells produce pro-inflammatory factors such as CC-chemokine ligand 2 (CCL2), interleukins (IL) IL-1β and IL-6, tumor necrosis factor α (TNFα) and oxidative stress3,4. Neutrophils and circulating monocyte-derived macrophages are recruited in large numbers to the infarct area, where they phagocytose necrotic cardiomyocytes and release proteases, in particular matrix metalloproteinase 9 (MMP-9) which breaks down collagen and facilitates further infiltration of inflammatory cells5–10.
A simplified way to, at least, roughly characterize macrophages is to decipher between pro-inflammatory and alternatively activated, pro-reparative subsets. The latter, starting to accumulate in the infarcted heart at day 3 express F4/80, CD64, CD206, arginase 1 and myeloid-epithelial-reproductive tyrosine kinase (MERTK)11–13. Those macrophages secrete anti-inflammatory, pro-fibrotic and pro-angiogenic factors, such as IL-10, transforming growth factor β, vascular endothelial growth factor, and MMPs—thereby, resolving inflammation and promoting repair mechanisms10,14,15. The post-MI inflammatory resolution process must be timely and tightly regulated to pave the way for appropriate wound healing and formation of a stable scar16.
Classical cannabinoid receptors contribute to post-MI wound healing via their function on immune and cardiovascular cells, with CB1 activation shown to be rather pro-inflammatory and CB2 promoting anti-inflammatory effects17–19. GPR55 was originally reported as a putative novel receptor for endocannabinoids and cannabinoid-related ligands, although some controversy exists about its cannabinoid binding activities20. An additional endogenous ligand for this receptor is lysophosphatidylinositol (LPI)20. The role of GPR55 in wound healing following cardiac injury is poorly investigated. In metabolic diseases, tissue expression of GPR55 and circulating levels of LPI are elevated21,22. GPR55 expression has been reported on several immune cell subtypes. In human peripheral monocytes and natural killer cells, GPR55 signalling increases cytokine production, cell cytotoxicity, decreases monocyte endocytosis and synergizes with CB2 to promote neutrophil migration23. As to the heart, low-level Gpr55 mRNA expression has been detected in the rodent myocardium and in isolated neonatal cardiomyocytes24, while lack of GPR55 has been reported to affect cardiac contractility by impairing β1-adrenoceptor responsiveness25. Moreover, a correlation between intracellular Ca2+ mobilization and GPR55 stimulation with cannabinoids or LPI was demonstrated in isolated neonatal cardiomyocytes24. In rat hearts ex vivo, LPI infused directly via the coronary circulation 10 min prior to ischaemia and subsequent reperfusion (I/R) increased infarct size26. In contrast, administration of cannabidiol (CBD), a GPR55 antagonist, has been shown to reduce infarct size post I/R in rats in vivo27,28. Another study reported an improved cerebral blood flow following experimental stroke when mice were injected with CBD29. The rising popularity of prescription-free CBD together with the clinical application of the US Food and Drug Administration-approved CBD drug Epidiolex emphasize the urge to elucidate how lack of functional GPR55 signalling affects the cardiovascular system.
In the present study we characterized the cardiac and immunological phenotype of naïve GPR55 deficient mice and investigated whether lack of GPR55 affects infarct size, wound healing kinetics and concurrently maladaptive remodelling post-MI. To elicit the effect of GPR55 on acute inflammation kinetics, we examined the immune profile of GPR55 deficient mice under naïve conditions and after 1 and 3 days of permanent MI. Moreover, we investigated the impact of GPR55 deficiency on early hypertrophy as well as on long-term structural and functional outcome 28 days post-MI.
Results
GPR55 deficiency leads to bradycardia, LV dilatation, pre-stretch and promotes a pro-inflammatory phenotype
We first confirmed Gpr55 mRNA expression in different organs of WT mice. Spleen and bone marrow showed the highest transcript levels, while low level receptor expression was noted in heart, liver, kidney and perigonadal visceral adipose tissue (see Supplementary Fig. S1). The analysis of sorted cardiac cells revealed detectable Gpr55 expression in all subsets isolated, including resident cardiac macrophages, cardiomyocytes and endothelial cells with fibroblasts exhibiting the lowest expression level (see Supplementary Fig. S1).
In naïve mice, GPR55 deficiency was associated with increased body weight, heart weight, LV mass and enlarged end-diastolic, but not end-systolic left ventricular volume and diameter (LVID) in the presence of a significantly decreased heart rate (Fig. 1a–c, Table 1) without changes in the functional parameters cardiac output, left ventricular (LV) ejection fraction (EF) and fractional shortening (FS) (see Supplementary Table S1). Of note, GPR55−/− mice were not only bradycardic under isoflurane inhalation, but also after isoflurane withdrawal when being awake (Fig. 1d). The increased diastolic volume in the absence of GPR55 was accompanied by enhanced atria and lung weight under baseline conditions per se, but not after normalisation against body weight (Table 1). Moreover, plasma albumin level and plasma volume were unaffected by the receptor deficiency (see Supplementary Fig. S2). The dilated phenotype in the absence of GPR55 therefore does most presumably not originate from excessive fluid accumulation, but rather from altered diastolic LV wall-stretch and filling dynamics. In support of this hypothesis, cardiomyocytes isolated from GPR55−/− mice exhibited an enhanced diastolic sarcomere length under physiological pacing frequencies (Fig. 1e–g) and a distinct reduction in time from peak contraction to 50% and 90% relaxation under each frequency applied when compared to WT cardiomyocytes (see Supplementary Fig. S3). On the contrary, while Ca2+ transient amplitude was enhanced in GPR55−/− myocytes, diastolic Ca2+ and time from peak tension to 50% and 80% Ca2+ decline were completely unaffected by GPR55 deficiency (see Supplementary Fig. S3). The Ca2+-contraction-relations clearly indicate that the observed contractile changes originate from a direct impact of GPR55 on myofilament calcium sensitivity. Herein, we confirm for the first time a cell-specific and contractile, myofilament function of GPR55 in adult murine cardiomyocytes.
| WT | GPR55−/− | |
|---|---|---|
| Body dimensions | ||
| n | 8 | 11 |
| Body weight [g] | 18.3 ± 0.2 | 21.7 ± 0.8* |
| Heart chamber weights | ||
| n | 8 | 11 |
| Heart [mg] | 90.9 ± 2.4 | 101.9 ± 2.6* |
| Atria [mg] | 6.9 ± 0.4 | 8.6 ± 0.5* |
| Wet organ weights | ||
| n | 8 | 11 |
| Lungs [mg] | 120.0 ± 7.6 | 153.8 ± 9.5* |
| Liver [mg] | 1001 ± 28 | 933 ± 45 |
| Kidney [mg] | 94.5 ± 3.2 | 114.2 ± 3.6* |
| Spleen [mg] | 68.0 ± 2.1 | 70.2 ± 5.4 |
| Dry organ weights | ||
| n | 8 | 11 |
| Lungs [mg] | 27.3 ± 0.7 | 31.5 ± 1.0* |
| Liver [mg] | 329 ± 11 | 314 ± 14 |
| Kidney [mg] | 26.0 ± 0.5 | 28.5 ± 1.7 |
| Wet organ weights normalized to body weight [mg/g] | ||
| n | 8 | 11 |
| Heart | 5.0 ± 0.1 | 4.7 ± 0.2 |
| Lungs | 6.6 ± 0.4 | 7.3 ± 0.7 |
| Spleen | 3.7 ± 0.1 | 3.2 ± 0.2* |
To determine a potential impact of GPR55 on immune homeostasis, basal cardiac and splenic immune cell composition was assessed by flow cytometry. GPR55 deficient hearts exhibited a significantly higher abundance of leukocytes in general and, in particular, of macrophages and neutrophils compared to WT hearts (Fig. 1h, see Supplementary Fig. S2). This was accompanied by distinct up-regulation of Mmp-9, known to be expressed by macrophages and neutrophils, and the chemokine Ccl2 (see Supplementary Fig. S2). Moreover, GPR55−/− mice had increased leukocyte numbers in lymphoid organs, while ratios between splenic myeloid (CD11b+) and lymphoid (CD11b−) cells were comparable between the genotypes (Fig. 1i). The increased leukocyte (CD45+) abundance in spleens of GPR55−/− mice was associated with elevated transcript levels of the pro-inflammatory cytokines Il-1β, Il-6 and Ifnγ and a concurrent reduction of the anti-inflammatory marker Il-10 (Fig. 1j). We may speculate that the observed impact on pro-inflammatory features and processes partially result from a volume-induced stretch of the myocardium in the absence of GPR55. However, a contribution of GPR55 to the development of LV volume overload and the associated immune response requires further investigation of the receptor in experimental overload settings to underpin our assumptions.
GPR55 deficiency does not affect initial infarct size, neutrophil or monocyte infiltration kinetics post-MI
To investigate the role of GPR55 during acute inflammation and subsequent wound healing following MI, global GPR55−/− mice and their WT littermates were assigned to left anterior descending artery (LAD) ligation to induce a permanent MI for 1 or 3 days (Fig. 2a). Naïve, age-matched WT and GPR55−/− littermates served for baseline comparison (no MI). First, we confirmed comparable initial infarct sizes at day 1 post-MI between the genotypes, as assessed via TTC staining of the heart (Fig. 2b,c).
As expected, 1 day after MI onset WT mice exhibited a pronounced acute inflammatory response at the site of injury in the LV, as shown by distinct up-regulation of Il-1b, Ccl2, Il-6 and Tnfα transcription compared to their corresponding no MI group. This acute response was partly mitigated in GPR55−/− mice at this time point (Fig. 2d). While the initial burst in cardiac cytokine and chemokine expression in WT decreased 3 days post-MI, these markers remained elevated in GPR55 deficient mice. Moreover, lack of GPR55 significantly up-regulated the anti-inflammatory cytokine Il-10 at this time-point.
Next, we assessed the impact of GPR55 deficiency on cardiac and circulating myeloid counts as a measure of their release and recruitment to the infarcted heart. WT mice showed the expected MI triggered increase in circulating neutrophil counts and plasma MPO levels. In contrast, the sustained subtle volume-overload in GPR55−/− mice under no MI conditions was already associated with blood neutrophil counts and activity comparable to the post-MI WT phenotype. This could not be further potentiated by the acute ischaemic injury (Fig. 2e, f, see Supplementary Fig. S2). In addition, LV infiltrating neutrophils during the acute innate immune response, which peaked 1 to 3 days post-MI, remained unaffected by GPR55 deficiency (Fig. 2g). Blood monocyte numbers in GPR55−/− mice were slightly lower at day 1, yet comparable 3 days post-MI. Moreover, neither cardiac monocyte counts in general, nor ratio between classical Ly6Chigh and non-classical Ly6Clow subsets or splenic mobilization thereof was affected by the absence of GPR55 during acute inflammation (Fig. 2f-h, see Supplementary Fig. S4). These observations suggest GPR55 not to impact on myeloid cell recruitment to the infarcted myocardium.
GPR55 deficiency promotes cardiac expansion of pro-repair macrophages post-MI
Despite comparable kinetics of LV neutrophil and monocyte accumulation, GPR55−/− hearts surprisingly displayed increased macrophage counts 3 days post-MI. This was reflected by concomitantly more abundant CD206+ and MERTK+ subsets when compared to WT hearts (Fig. 3a,b). Increased Mertk expression in GPR55 deficient heart could further be confirmed via qPCR of whole heart lysate at day 3 following MI (Fig. 3c). The mannose receptor CD206 represents a hallmark of alternatively activated, rather pro-reparative macrophages while MERTK is a phagocytosis receptor for apoptotic cells, which is crucial for tissue repair. Thus, our observations may hint toward a premature induction of reparative processes post-MI in the absence of GPR55, which is paralleled by a delayed pro-inflammatory cytokine response.
Haematopoietic GPR55 depletion promotes cardiac expansion of pro-repair macrophages post-MI
To assess the specific role of haematopoietic GPR55 in regulating cardiac macrophage expansion and polarization, we generated WT > WT and KO > WT bone marrow chimaera and subjected them to 3 days permanent MI (Fig. 4a). Sole haematopoietic depletion of GPR55 recapitulated the effects of global GPR55 deficiency regarding elevated numbers of CD206+ and MERTK+ macrophage subsets in KO > WT hearts when compared to WT > WT hearts (Fig. 4b). Moreover, increased Mertk transcription in 3-day infarcted KO > WT hearts could be confirmed via qPCR analyses (Fig. 4c), along with elevated cytokine and chemokine expression (Fig. 4d).
GPR55 deficiency promotes extracellular matrix turn-over during early remodelling post-MI
Tightly regulated acute inflammation and its adequate resolution pave the way for subsequent repair mechanisms, including not only reprograming pro-inflammatory to pro-reparative macrophages, but also fibrosis for the formation of a stable scar in the infarct area. Yet, dys-regulated extracellular matrix deposition may lead to infarction expansion and LV dilatation. At day 3 post-MI, GPR55 deficiency significantly enhanced MI-induced transcription of Mmp-9, a potent trigger of and predictor for infarction expansion and therefore progressive maladaptation (Fig. 5a). This was accompanied by increased Col Iα2 and Col IIIα1 expression compared to WT mice. Ratio between Col Iα2/Col IIIα2 remained unaffected by the genotype. Enhanced Mmp-9 and collagen marker expression after MI could be mimicked by sole haematopoietic GPR55 depletion in bone marrow chimaera (Fig. 5b). These data hint toward an exaggerated matrix turnover early after the ischaemic insult and again underpin the assumption that lack of GPR55 is associated with a dysregulated healing response.
GPR55 deficiency impairs early foetal gene expression and aggravates late structural remodelling post-MI
Not only a tightly regulated acute inflammation and matrix deposition, but also an adequate induction of compensatory hypertrophy crucially determines the outcome post-MI. To examine the impact of GPR55 on early hypertrophy and long-term remodelling post-MI, a second subset of GPR55−/− and WT mice was characterized based on hypertrophic features 1 day and 28 days post-MI or sham surgery, respectively (Fig. 6a). LV expression pattern of foetal genes revealed that GPR55 deficiency mitigated the MI triggered re-expression of Nppa (ANP) and Myh7 (β-MHC) and tended to reduce Myh7/Myh6 ratio, while Nppb (BNP) remained widely unaffected (Fig. 6b, Table 2). In contrast to the pro-inflammatory response, the pro-hypertrophic response was not delayed or shifted to a later time-point post-MI (data not shown) but rather attenuated in general.
| Sham | MI | |||
|---|---|---|---|---|
| WT | GPR55 − / − | WT | GPR55 − / − | |
| n | 6–7 | 7–9 | 5–6 | 6–8 |
| Myh7/Myh6 | 1.1 ± 0.2 | 1.2 ± 0.4 | 11.8 ± 5.3* | 4.9 ± 2.7 |
| Myh7 | 1.2 ± 0.4 | 2.8 ± 0.7 | 5.9 ± 1.4 | 2.9 ± 0.7# |
| Nppb | 1.8 ± 0.8 | 1.3 ± 0.5 | 3.2 ± 0.6 | 1.6 ± 0.5 |
| Nppa | 1.8 ± 0.6 | 2.3 ± 0.5 | 23.2 ± 7.7* | 8.2 ± 2.7# |
Measurement of cardiomyocyte cross sectional area and diameter confirmed MI triggered hypertrophy in WTs in comparison to WT sham mice (Fig. 6c,d). Interestingly, independent of the surgical intervention, GPR55−/− mice exhibited larger cardiomyocytes than their corresponding WT groups, with no evident enlargement by MI. A similar trend could be observed for heart weight per se and normalized against tibia length and body weight (Fig. 6e, see Supplementary Table S2). Consistent with this observation, echocardiography could not reveal an additive effect of MI on the pre-existing higher LV mass in GPR55−/− mice under sham-conditions (Fig. 7a). Furthermore, the enlarged end-diastolic diameter and volume, which was already observed under naïve conditions (Fig. 1a), was also noted at early time-points after sham surgery, accompanied by an early increase in end-systolic chamber size and filling. This difference between the sham groups was blunted by physiological age-dependent increase in WT heart size from day 7 onwards. These observations most likely count for first, the lack of evident MI triggered LV dilatation in GPR55−/− mice during the first 7 days post MI and second the pronounced dilatation seen in WTs during this remodelling stage when compared to their respective sham groups. Nonetheless, GPR55 deficiency significantly aggravated post-MI LV dilatation during the late remodelling phase (Fig. 7b–d). While lack of GPR55 per se did not affect LV wall thickness over time in the sham group compared to WT sham, post-MI maladaptation in GPR55−/− mice was additionally characterized by a drastic and early thinning of both, the LV anterior wall (LVAW) and the intraventricular septum (IVS), hinting toward aggravated infarction expansion (Fig. 7b,c, see Supplementary Fig. S5). Of note, while MI expectedly reduced EF and FS in WTs compared to their sham controls, we also observed a reduced LV function in GPR55−/− mice early after sham-surgery as consequence of the increased end-systolic volume. Nevertheless, MI triggered a further functional decline in GPR55 deficient mice, as verified by lower EF in comparison to the WT MI group, which was most pronounced at 7 days post MI (Fig. 7e).
Discussion
We provide novel evidence that the lipid receptor GPR55 crucially affects the heart during homeostasis and post-MI pathophysiology. Our data hint toward a relevant role for GPR55 signalling in both, haematopoietic cells and cardiomyocytes in regulating cardiac function and remodelling. Baseline phenotyping suggests GPR55 to affect preload and chronotropy. Increase in end-diastolic LV volume and stroke volume presumably compensate for the reduced heart rate to maintain cardiac output in GPR55−/− mice. Of note, our observation that GPR55−/− mice exhibit low heart rates (367 ± 14 bpm), compared to WT (515 ± 5 bpm and an average EF of 63%), initially derived from echocardiographic recordings under 1.5% isoflurane inhalation. In contrast, Walsh et al. reported, under ketamine/xylazine anaesthesia during catheterization, an increased HR in naïve GPR55−/− mice (420 ± 7 bpm) compared to WT, with the latter exhibiting a rather low frequency of merely 395 ± 7 bpm, associated with an EF of only 50%25. It is conceivable that the distinct examination techniques (non-invasive vs. invasive) and/or the differing HR suppressing impact of the applied anaesthetics might account for the divergent observations between the two studies. However, heart rate recordings after isoflurane withdrawal in conscious mice confirmed GPR55 to affect chronotropy widely independent of an anaesthesia interaction in our study (WT 564 ± 10 bpm vs. GPR55−/− 366 ± 13 bpm). GPR55 deficiency might generate the negative chronotropy by dampening neurotransmitter release and reduced adrenergic signalling, while GPR55 stimulation with LPI increases transmitter exocytosis, as shown in PC12 cells30.
The reason for increased diastolic volume and diameter in GPR55−/− mice in the absence of evident valvular defects could be twofold: First, a pre-established increase in blood volume and excessive fluid accumulation in the body; Second, impaired lusitropy and/or a prolonged filling phase creating a pre-stretch, maybe resulting from altered ion sensitivity. Similar heart, atria and lung weight to body weight ratios, as well as comparable plasma albumin level and plasma volumes rather rule out an excessive fluid accumulation in GPR55−/− mice as cause for the enhanced LV volume31–33. In contrast, after verifying GPR55 expression in adult murine cardiomyocytes, we observed an enhanced diastolic, but not systolic sarcomere length in GPR55−/− cardiomyocytes compared to WT myocytes. This was accompanied by an accelerated relaxation time and increased Ca2+ transient amplitude. Altered Ca2+ entry and intracellular Ca2+ mobilization in response to GPR55 stimulation with cannabinoids or LPI has been shown in isolated neonatal rat cardiomyocytes24. Moreover, transient expression of human GPR55 in HEK293 cells increases intracellular [Ca2+] and inhibits potassium M currents34. GPR55 deficiency might consequently modify lusitropy, diastolic filling and chronotropy by altering not only Ca2+ handling but also K+ efflux. Our data confirm for the first time a direct function of the receptor in adult murine cardiomyocytes and underpin the hypothesis that lack of the receptor manifests a pre-stretch of the left ventricle. We suppose GPR55 to regulate filling dynamics, thereby mediating LV volume-overload and wall stretch by modifying myofilament sensitivity. Moreover, we might speculate GPR55 deficiency not only to promote LV pre-stretch, but also to affect action potential duration and action potential rate, i.e. heart rate by altering ion handling and filament sensitivity.
Permanent LV volume-overload applies a constant mechanical wall stress, forcing cardiomyocytes to adapt by enlargement and inducing moderate myocardial inflammation triggering LV neutrophil infiltration, regulated by Tnfα and Ccl2, resulting in MMP activation35. Moreover, enhanced dilation-triggered wall tension in vivo as well as applied mechanical stretch in vitro promotes macrophage proliferation36. Thus, cardiomyocyte enlargement, elevated LV counts of macrophages and neutrophils—both known to express and secrete MMP-9, together with up-regulated Ccl2 and Mmp-9 transcription in unstressed GPR55−/− mice may support our hypothesis of a volume-overload phenotype. GPR55−/− mice also exhibited higher femoral, splenic (not shown), circulating and cardiac neutrophil numbers and elevated plasma MPO level when compared to basal WTs, underpinning augmented neutrophil activity. Our data suggest for the first time, that functional GPR55 signalling is required for the maintenance of physiological immune homeostasis in conditions where the heart is exposed to moderate mechanical stretch. We therefore propose that GPR55 exerts direct cardiac effects, which in turn, might affect the immune system even under naïve conditions.
Following acute myocardial infarction, GPR55 deficiency did not affect the initial infarct size in our study. The literature states conflicting results regarding the impact of GPR55 on infarct size. However, these results mainly emerge from ischaemia/reperfusion (I/R) studies26,28,37. The controversy might also be related to the fact that ligands used to activate or antagonize GPR55 are targeting additional receptors, implying that the receptor responsible for the reported infarct size alterations is not entirely clear. Despite comparable infarct sizes in our study, GPR55−/− deficiency shifted the onset of acute inflammation from day 1 to day 3 at the site of injury, which is attributable to haematopoietic GPR55 expression. Somewhat surprising, this delayed and exacerbated pro-inflammatory response did not alter LV infiltration kinetics of monocytes and neutrophils. Balenga et al. suggested that a CB2-GPR55 cross-talk is essential for neutrophil migration to the site of injury, based on their in vitro migration assays using human blood neutrophils23. Our data do not support an impaired neutrophil recruitment in absence of GPR55, at least not in the context of permanent LAD ligation in mice. While GPR55 depletion had no effect on myeloid cell infiltration into the infarcted heart, it promoted expansion of alternatively activated macrophages at day 3 post-MI, the time-point when Ly6Chigh monocyte derived rather pro-inflammatory macrophages are described to accumulate following ischaemia10,38. The observed expansion of CD206+ macrophages in GPR55−/− mice was associated with enhanced MERTK expression, a phagocytosis receptor that plays a crucial role in cardiac healing post-MI39. Haematopoietic depletion of GPR55 could mimick the macrophage expansion in the heart seen in global GPR55 knockout mice. The higher abundance of pro-reparative macrophages, together with elevated Mmp-9 and Col levels in absence of GPR55 hint toward a role of the receptor in regulating matrix turn-over and macrophage polarization. Blocked GPR55 signalling has already been linked to enhanced MMP-9 expression under inflammatory conditions40. The molecular mechanisms polarizing macrophages toward a pro-fibrotic phenotype and thereby promoting premature wound healing, however, remain to be further investigated. We may only speculate that a disturbed Ca2+ signalling in cardiac macrophages in absence of GPR55 may promote their polarization to an alternative phenotype. So far, studies addressing an immuno-modulatory role for GPR55 have mainly focused on proliferation, lymphocyte function and neutrophils in haematopoietic and peripheral organs in chronic disease settings41–43. Our data indicate for the first time a GPR55-dependent regulation of macrophage expansion and phenotype in the heart. In support of a role for GPR55 in cardiac macrophages, we confirmed its gene expression in macrophages sorted from naïve hearts. We may speculate that GPR55 is also expressed by de novo recruited bone-marrow derived macrophages to the infarcted myocardium, although we did not directly confirm this due to the lack of specific antibodies for flow cytometric detection within ischaemic cardiac tissue.
In addition to the haematopoietic role of GPR55 during MI healing, we also observed an impact of the receptor on cardiomyocyte morphology and signalling. GPR55−/− mice exhibited enlarged cardiomyocytes under sham conditions. A further MI-triggered increase in myocyte size, i.e. pathological hypertrophy, was blunted in the absence of GPR55. In support of a crucial role for GPR55 in regulating hypertrophic responses, we also noticed an attenuated re-activation of foetal genes in GPR55−/− hearts. The reported dysregulated healing response, encompassing premature LV expansion of pro-reparative macrophages combined with increased transcription of ECM factors and prolonged exacerbated chemokine production could be clearly attributed to a haematopoietic role of GPR55. Aggravated long-term remodelling, including exacerbated LV dilatation, infarct thinning and expansion and a more pronounced functional decline, most likely derives from a combination of the haematopoietic impact, mitigated compensatory cardiomyocyte hypertrophy and the basal volume-overloaded cardiac phenotype in the absence of GPR55. In addition, it is quite conceivable that dysregulated glucose uptake and insulin secretion may contribute to the harmful effects of GPR55 deficiency on post-MI outcome. Given that GPR55 activation reduces glucose levels, stimulates insulin secretion from pancreatic β cells, promotes insulin signalling in myotubes, and contributes to manifestation of obesity and diabetes, the receptor could also impact on the metabolically imbalanced myocardium upon ischaemic injury20,21,44. Herein, the receptor might exert peripheral effects (substrate supply) or direct cardiomyocyte effects by affecting glucose and fatty acid up-take and utilization. This however needs to be elucidated by further cardiac studies. In conclusion, our study alludes for the first time toward a crucial role for GPR55 in regulating heart rate, maintaining adequate LV load and stretch, inducing compensatory hypertrophy, synchronizing wound healing and limiting maladaptation post-MI via synergistic cardiac and haematopoietic effects. Thus, targeted GPR55 stimulation might beneficially impact on patient’s clinical outcome post-MI (for a graphical summary see Supplementary Fig. S6).
Finally, we realize that our study has several limitations. First, in this study we applied permanent LAD ligation to induce MI. Even though I/R models are assessed more clinically relevant, the widely used permanent LAD occlusion allows utter tracing of the wound healing and remodelling effects elicited by genetic, pharmacological, or surgical interventions. This in turn can provide insights into the role of specific cell types, signalling cascades and structural alterations triggered by ischaemia, preceding more defined therapeutically relevant approaches. Second, at this stage we cannot exclude that the global constitutive GPR55 deficiency provokes compensatory mechanisms, such as the up-regulation of other cannabinoid-sensitive lipid receptors or lipid mediator synthesizing and degrading enzymes. Targeted GPR55 blockade and/or stimulation approaches as well as cell-specific receptor depletion studies are warranted to further decipher the exact role of the receptor in post-MI wound healing. Third, we suggest GPR55 to contribute to the development of LV volume overload. Further studies investigating the role of GPR55 in experimental overload settings are required to underpin our assumptions.
Methods
Study population
GPR55−/− mice on C57BL/6J background were purchased from the European Mouse Mutant Archive (EM:02355). The targeted mutation was generated in 129SvEvBrd-derived embryonic stem cells via insertion of a targeting cassette depleting the entire GPR55 encoding sequence in exon 1 (International strain designation: B6; 129S5-Gpr55tm1Lex/leg) and back-crossing of offspring with C57BL/6J WT mice. WT littermates were obtained by heterozygous breeding and served as controls throughout the study. Mice were genotyped after weaning by PCR to amplify a 422 bp region of the WT and a 301 bp region of the mutant allele. WT and GPR55−/− female mice were included in this study. No signs of infertility, pre-mature mortality, developmental defects or sex-specific differences in basal phenotypes were observed in a pilot study. All animal procedures were performed conform to the guidelines from Directive 2010/63/EU and the ARRIVE guidelines, and approved by the government of Upper Bavaria (ROB-55.2.2532.Vet_02-13-176 and 18-114).
Echocardiography
Echocardiographic scans were acquired with the VisualSonicsVevo® 3100 imaging system (Scanhead: RMV707B, 15–45 MHz, cardiac mouse) and analysed as described previously by Puhl et al.45. For serial scans mice were basally scanned 2 to 3 days before surgery and 3, 7, 14 and 28 days post-intervention. To assess heart rate under conscious conditions, mice were initially anaesthetized and monitored as described above and ECG recordings were continued upon isoflurane withdrawal and regaining consciousness.
MI induction
GPR55−/− and WT mice were randomly assigned to either permanent ligation of the left anterior descending coronary artery (LAD) using a 7-0 thread to induce MI or to sham operation, respectively. Briefly, under deep anaesthesia (medetomidin/midazolam/fentanyl; 0.5/5.0/0.05 mg/kg; intraperitoneally) the thorax was opened in the third intercostal room and the LAD was ligated 2 mm below the left atrium. The intercostal space and skin were closed with single knot sutures with 5-0 silk. Anaesthesia was antagonized by flumazenil/atipamezol (0.1/0.5 mg/kg; intraperitoneally). For analgesia buprenorphine (0.05 mg/kg body weight; subcutaneously) was injected immediately, 6 h, 24 h and 32 h and meloxicam (0.2 mg/kg; subcutaneously) 24 h after surgery. Sham animals underwent the same procedure without occlusion of the LAD.
Bone marrow transplantation
Bone marrow chimaera were generated by lethal irradiation (5 Gy; twice within 8 h) of female WT mice, aged 10 weeks, and subsequent reconstitution with 2 × 106 bone marrow cells extracted from femurs of female, age matched global GPR55−/− mice (KO > WT) or WT donors (WT > WT). Mice received antibiosis (100 µg/ml neomycin and 10 µg/ml polymyxin B sulphate) via drinking water starting 1 week before and continuing 4 weeks after irradiation and bone marrow transplantation. After a recovery phase of 6 weeks following reconstitution, mice were subjected to permanent LAD ligation for 3 days.
Tissue sampling
Mice were euthanized by overdosed xylazine/ketamine (120/10 mg/kg body weight) anaesthesia. EDTA blood was collected from the right ventricle and split for flow cytometry (50 µl) and plasma collection. After LV puncture and perfusion with PBS, the heart, lungs, spleen, liver, left kidney, femoral bone marrow and left tibia were excised. Wet and dry weight of lungs, liver and the left kidney were determined to assess tissue congestion. A description of tissue processing and LV partition for different analyses can be found in Supplementary Methods and Supplementary Fig. S7.
Flow cytometry
Bone marrow cells were collected from one femur by centrifugation for 2 min at 9000×g. Excised spleens were mashed through a 70 µm filter. EDTA blood, bone marrow cells and spleens were subjected to erythrolysis. Hearts were minced with fine scissors and digested, as described previously19. The entire list of antibodies used and the applied gating strategies can be found in Supplementary Methods and the Supplementary Fig. S8.
Histology
Cardiomyocyte cross-sectional area and diameter were assessed using the LEICA LAS software following staining with haematoxylin and eosin (H&E) in paraformaldehyde-fixed and paraffin-embedded transverse midventricular tissue slices (5 µm), as described previously46.
Gene expression analyses
For qPCR analysis of whole cell lysates, the respective tissue was homogenised, lysed and RNA isolated. Following reverse transcription 2.3 ng cDNA per sample and gene were used for TaqMan PCR amplification. All samples were run in duplicates. mRNA expression was normalized per sample against Gapdh and relative quantitation of gene expression was calculated using the comparative ∆∆CT method. Expression data based on whole tissue mRNA are displayed as fold over WT no MI, WT Sham or WT > WT, as appropriate. The entire list of qPCR primers used can be found in Supplementary Methods.
ELISA
Plasma MPO levels were determined using a standard ELISA kit (Duoset, R&D Systems).
Sarcomere length and Ca2+ transient measurement
LV myocytes were isolated from adult WT and GPR55−/− mice with an isolation protocol modified from O’Connell et al. (AfCS Research Reports; Vol. 1 No. 5 CM) according to Nickel et al.47,48 and Kohlhaas et al.49. Isolated cardiomyocytes were paced by electrical field stimulation and sarcomere length was recorded using a customized IonOptix system as described previously47,49. [Ca2+]c was measured by incubating cells with indo-1 AM (5 µmol/l) for 20 min at 25 °C (λexcitation = 340 nm, λemission = 405/485 nm).
Data analysis
Experimental animals were randomly assigned to treatment groups. Group sizes throughout the study are n ≥ 5. Continuous data are presented as mean ± SE. To determine differences between two groups, unpaired student’s t-test was performed. For multiple group comparisons involving two independent variables and for parallel repeated measures to determine the significance for individual time points, two-way ANOVA was applied with Sidak’s post-hoc test after F-test of variance was confirmed as p < 0.05. For repeated (paired) Ca2+ and sarcomere length measurements two-way ANOVA with Bonferroni’s post hoc test was applied. All calculated p-values are two-sided. Differences with a p < 0.05 were considered statistically significant. All analyses were performed with Microsoft Excel 2010 and GraphPad Prism 8.0 software.
Ethics approval
All animal procedures were performed conform to the ARRIVE guidelines, Directive 2010/63/EU and to the government of Upper Bavaria (ROB-55.2.2532.Vet_02-13-176 and 18-114).
Supplementary Information
Untitled section
Acknowledgements
The graphical summary of experimental findings was created with BioRender.com.
Funding
Open Access funding enabled and organized by Projekt DEAL. This work was supported by the Deutsche Forschungsgemeinschaft (STE-1053/6-1 and SFB 1123 to S.S.; Ma 2528/7-1, SFB 894 and TRR-219 to C.M.), the FöFoLe programme (to M.H. and L.M.K.), the Friedrich-Baur funding of the Ludwig-Maximilians-Universität Medical Faculty (to SL. P.), the German Ministry of Research and Education (DZHK FKZ 81Z0600205 to S.S.; BMBF 01EO1504 to C.M.) and the Barth Syndrome Foundation to C.M.
Data availability
The data underlying this article are available in the article and in its online supplementary material.
Competing interests
The authors declare no competing interests.
Footnotes
Footnote Group
Supplementary Information
The online version contains supplementary material available at 10.1038/s41598-021-93755-y.
References
Untitled section
References
- 1.Eefting F, et al. Role of apoptosis in reperfusion injury. Cardiovasc. Res. 2004;61:414–426. doi: 10.1016/j.cardiores.2003.12.023.
- 2.Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation. 2000;101:2981–2988. doi: 10.1161/01.cir.101.25.2981.
- 3.Huang S, Frangogiannis NG. Anti-inflammatory therapies in myocardial infarction: Failures, hopes and challenges. Br. J. Pharmacol. 2018;175:1377–1400. doi: 10.1111/bph.14155.
- 4.Ong SB, et al. Inflammation following acute myocardial infarction: Multiple players, dynamic roles, and novel therapeutic opportunities. Pharmacol. Ther. 2018;186:73–87. doi: 10.1016/j.pharmthera.2018.01.001.
- 5.Puhl SL, Steffens S. Neutrophils in post-myocardial infarction inflammation: Damage vs. resolution? Front. Cardiovasc. Med. 2019;6:25. doi: 10.3389/fcvm.2019.00025.
- 6.Vanhoutte D, Schellings M, Pinto Y, Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: A temporal and spatial window. Cardiovasc. Res. 2006;69:604–613. doi: 10.1016/j.cardiores.2005.10.002.
- 7.Deleon-Pennell KY, Altara R, Yabluchanskiy A, Modesti A, Lindsey ML. The circular relationship between matrix metalloproteinase-9 and inflammation following myocardial infarction. IUBMB Life. 2015;67:611–618. doi: 10.1002/iub.1408.
- 8.Lindsey ML. Assigning matrix metalloproteinase roles in ischaemic cardiac remodelling. Nat. Rev. Cardiol. 2018;15:471–479. doi: 10.1038/s41569-018-0022-z.
- 9.Leuschner F, et al. Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. J. Exp. Med. 2012;209:123–137. doi: 10.1084/jem.20111009.
- 10.Frodermann V, Nahrendorf M. Macrophages and cardiovascular health. Physiol. Rev. 2018;98:2523–2569. doi: 10.1152/physrev.00068.2017.
- 11.Hilgendorf I, et al. Ly-6Chigh monocytes depend on Nr4a1 to balance both inflammatory and reparative phases in the infarcted myocardium. Circ. Res. 2014;114:1611–1622. doi: 10.1161/CIRCRESAHA.114.303204.
- 12.Dehn S, Thorp EB. Myeloid receptor CD36 is required for early phagocytosis of myocardial infarcts and induction of Nr4a1-dependent mechanisms of cardiac repair. FASEB J. 2018;32:254–264. doi: 10.1096/fj.201700450R.
- 13.Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011;11:723–737. doi: 10.1038/nri3073.
- 14.Swirski FK, Nahrendorf M. Imaging macrophage development and fate in atherosclerosis and myocardial infarction. Immunol. Cell Biol. 2013;91:297–303. doi: 10.1038/icb.2012.72.
- 15.Wan E, et al. Enhanced efferocytosis of apoptotic cardiomyocytes through myeloid-epithelial-reproductive tyrosine kinase links acute inflammation resolution to cardiac repair after infarction. Circ. Res. 2013;113:1004–1012. doi: 10.1161/CIRCRESAHA.113.301198.
- 16.Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ. Res. 2012;110:159–173. doi: 10.1161/CIRCRESAHA.111.243162.
- 17.Pacher P, Steffens S, Hasko G, Schindler TH, Kunos G. Cardiovascular effects of marijuana and synthetic cannabinoids: The good, the bad, and the ugly. Nat. Rev. Cardiol. 2018;15:151–166. doi: 10.1038/nrcardio.2017.130.
- 18.Puhl SL. Cannabinoid-sensitive receptors in cardiac physiology and ischaemia. Biochim. Biophys. Acta Mol. Cell Res. 2019 doi: 10.1016/j.bbamcr.2019.03.009.
- 19.Horckmans M, et al. Pericardial adipose tissue regulates granulopoiesis, fibrosis, and cardiac function after myocardial infarction. Circulation. 2018;137:948–960. doi: 10.1161/CIRCULATIONAHA.117.028833.
- 20.Shore DM, Reggio PH. The therapeutic potential of orphan GPCRs, GPR35 and GPR55. Front. Pharmacol. 2015;6:69. doi: 10.3389/fphar.2015.00069.
- 21.Henstridge CM, Brown AJ, Waldhoer M. GPR55: Metabolic help or hindrance? Trends Endocrinol. Metab. 2016;27:606–608. doi: 10.1016/j.tem.2016.04.012.
- 22.Moreno-Navarrete JM, et al. The L-alpha-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. Diabetes. 2012;61:281–291. doi: 10.2337/db11-0649.
- 23.Balenga NA, et al. GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res. 2011;21:1452–1469. doi: 10.1038/cr.2011.60.
- 24.Yu J, et al. Differential activation of cultured neonatal cardiomyocytes by plasmalemmal versus intracellular G protein-coupled receptor 55. J. Biol. Chem. 2013;288:22481–22492. doi: 10.1074/jbc.M113.456178.
- 25.Walsh SK, Hector EE, Andreasson AC, Jonsson-Rylander AC, Wainwright CL. GPR55 deletion in mice leads to age-related ventricular dysfunction and impaired adrenoceptor-mediated inotropic responses. PLoS ONE. 2014;9:e108999. doi: 10.1371/journal.pone.0108999.
- 26.Robertson-Gray OJ, et al. l-alpha-Lysophosphatidylinositol (LPI) aggravates myocardial ischemia/reperfusion injury via a GPR55/ROCK-dependent pathway. Pharmacol. Res. Perspect. 2019;7:e00487. doi: 10.1002/prp2.487.
- 27.Durst R, et al. Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2007;293:H3602–H3607. doi: 10.1152/ajpheart.00098.2007.
- 28.Walsh SK, Hepburn CY, Kane KA, Wainwright CL. Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion. Br. J. Pharmacol. 2010;160:1234–1242. doi: 10.1111/j.1476-5381.2010.00755.x.
- 29.Sultan SR, Millar SA, England TJ, O'Sullivan SE. A systematic review and meta-analysis of the haemodynamic effects of cannabidiol. Front. Pharmacol. 2017;8:81. doi: 10.3389/fphar.2017.00081.
- 30.Ma MT, et al. Differential effects of lysophospholipids on exocytosis in rat PC12 cells. J. Neural Transm. (Vienna) 2010;117:301–308. doi: 10.1007/s00702-009-0355-1.
- 31.Jochmann S, et al. Assessing the role of extracellular signal-regulated kinases 1 and 2 in volume overload-induced cardiac remodelling. ESC Heart Fail. 2019;6:1015–1026. doi: 10.1002/ehf2.12497.
- 32.Mohamed BA, et al. Molecular and structural transition mechanisms in long-term volume overload. Eur. J. Heart Fail. 2016;18:362–371. doi: 10.1002/ejhf.465.
- 33.Miller WL. Fluid volume overload and congestion in heart failure: Time to reconsider pathophysiology and how volume is assessed. Circ. Heart Fail. 2016;9:e002922. doi: 10.1161/CIRCHEARTFAILURE.115.002922.
- 34.Lauckner JE, et al. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. U.S.A. 2008;105:2699–2704. doi: 10.1073/pnas.0711278105.
- 35.Chen Y, et al. Tumor necrosis factor-alpha produced in cardiomyocytes mediates a predominant myocardial inflammatory response to stretch in early volume overload. J. Mol. Cell Cardiol. 2010;49:70–78. doi: 10.1016/j.yjmcc.2009.12.013.
- 36.Sager HB, et al. Proliferation and recruitment contribute to myocardial macrophage expansion in chronic heart failure. Circ. Res. 2016;119:853–864. doi: 10.1161/CIRCRESAHA.116.309001.
- 37.Lepicier P, Bouchard JF, Lagneux C, Lamontagne D. Endocannabinoids protect the rat isolated heart against ischaemia. Br. J. Pharmacol. 2003;139:805–815. doi: 10.1038/sj.bjp.0705313.
- 38.Yan X, et al. Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction. J. Mol. Cell Cardiol. 2013;62:24–35. doi: 10.1016/j.yjmcc.2013.04.023.
- 39.DeBerge M, et al. MerTK Cleavage on resident cardiac macrophages compromises repair after myocardial ischemia reperfusion injury. Circ. Res. 2017;121:930–940. doi: 10.1161/CIRCRESAHA.117.311327.
- 40.Montecucco F, et al. Treatment with the GPR55 antagonist CID16020046 increases neutrophil activation in mouse atherogenesis. Thromb. Haemost. 2016;116:987–997. doi: 10.1160/TH16-02-0139.
- 41.Yang H, Zhou J, Lehmann C. GPR55—A putative “type 3” cannabinoid receptor in inflammation. J. Basic Clin. Physiol. Pharmacol. 2016;27:297–302. doi: 10.1515/jbcpp-2015-0080.
- 42.Zhou J, Burkovskiy I, Yang H, Sardinha J, Lehmann C. CB2 and GPR55 receptors as therapeutic targets for systemic immune dysregulation. Front. Pharmacol. 2016;7:264. doi: 10.3389/fphar.2016.00264.
- 43.Guillamat-Prats R, Rami M, Herzig S, Steffens S. Endocannabinoid signalling in atherosclerosis and related metabolic complications. Thromb. Haemost. 2019;119:567–575. doi: 10.1055/s-0039-1678738.
- 44.Lipina C, et al. GPR55 deficiency is associated with increased adiposity and impaired insulin signaling in peripheral metabolic tissues. FASEB J. 2018 doi: 10.1096/fj.201800171R.
- 45.Puhl SL, Weeks KL, Ranieri A, Avkiran M. Assessing structural and functional responses of murine hearts to acute and sustained beta-adrenergic stimulation in vivo. J. Pharmacol. Toxicol. Methods. 2016;79:60–71. doi: 10.1016/j.vascn.2016.01.007.
- 46.Puhl SL, et al. Exercise attenuates inflammation and limits scar thinning after myocardial infarction in mice. Am. J. Physiol. Heart Circ. Physiol. 2015;309:H345–H359. doi: 10.1152/ajpheart.00683.2014.
- 47.Nickel AG, et al. Reversal of mitochondrial transhydrogenase causes oxidative stress in heart failure. Cell Metab. 2015;22:472–484. doi: 10.1016/j.cmet.2015.07.008.
- 48.Nickel AG, et al. CaMKII does not control mitochondrial Ca(2+) uptake in cardiac myocytes. J. Physiol. 2020;598:1361–1376. doi: 10.1113/JP276766.
- 49.Kohlhaas M, et al. Endogenous nitric oxide formation in cardiac myocytes does not control respiration during beta-adrenergic stimulation. J. Physiol. 2017;595:3781–3798. doi: 10.1113/JP273750.
Associated Data
Supplementary Materials
Data Availability Statement
The data underlying this article are available in the article and in its online supplementary material.